Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $47.5M rose 38.4% year over year, ahead of the +29.3% change in trailing-twelve-month research & development. Sequentially, it rose 44.0% from the prior quarter. Over 3 fiscal years it compounded at +58.7% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +38.4% holds above the trailing-twelve-month pace of +29.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 125.1M USD
- Year-over-year change
- +96.6%
- 3-year CAGR
- +58.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 125.1M | +96.6% |
| FY2024 | 2024-12-31 | 63.62M | +107.8% |
| FY2023 | 2023-12-31 | 30.62M | -2.2% |
| FY2022 | 2022-12-31 | 31.31M | — |
Research & Development vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's LTM Mar 2026 research & development of $111.11M is the 4th highest of the 6 companies compared; the peer median is $135.36M.
- Its year-over-year change of +29.3% is the 3rd highest of 6, against a peer median of +22.7%.
- Over three fiscal years its annual growth of +58.7% compares with a peer median of +26.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $188.07M | +22.3% | +26.8% | — | |
| LTM Mar 2026 | $145.36M | +345.0% | +69.4% | 1223.2% | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $111.11M | +29.3% | +58.7% | — |
| LTM Mar 2026 | $56.29M | +22.7% | +23.1% | — | |
| LTM Mar 2026 | $35.41M | +46.4% | +65.0% | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $135.36M | +22.7% | +26.8% | 654.7% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 31.31M | 30.62M | 63.62M | 125.1M |
| Selling, General & Admin | 6.34M | 9.27M | 18.77M | 30.51M |
| Operating Expenses | 37.66M | 39.89M | 82.39M | 155.6M |
| Depreciation & Amortization | 10K | 19K | 56K | 105K |
| EBITDA | (37.72M) | (51.96M) | (67.75M) | (137.63M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (37.66M) | (39.89M) | (82.39M) | (155.6M) |
| Operating Margin | — | — | — | — |
| Interest Income | 4K | 1.31M | 14.58M | 17.87M |
| Interest Expense | 112K | 0 | 0 | 0 |
| Other Income / Expenses | (188K) | (12.09M) | 14.58M | 17.87M |
| Income Before Tax | (37.84M) | (51.98M) | (67.81M) | (137.73M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1K | 5K | 187K | 217K |
| Net Income | (37.85M) | (51.99M) | (68M) | (137.95M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.73) | (1.00) | (1.25) | (2.52) |
| EPS (Diluted) | (0.73) | (1.00) | (1.25) | (2.52) |
| Weighted Avg Shares | 51.76M | 51.76M | 54.42M | 54.68M |
| Weighted Avg Shares (Diluted) | 51.76M | 51.76M | 54.42M | 54.68M |
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.